, Situation report: Ebola virus disease. Geneva: World Health Organization, World Health Organization, 2016.

D. Sissoko, C. Laouenan, E. Folkesson, M. Beavogui, A. Baize et al., Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-ofconcept trial in Guinea, PLoS Med, vol.13, p.26930627, 2016.

J. Dunning, S. B. Kennedy, A. Antierens, J. Whitehead, I. Ciglenecki et al., Experimental treatment of Ebola virus disease with brincidofovir, PLoS ONE, vol.11, p.27611077, 2016.

, Multi-National PREVAIL II Study Team. A Randomized, controlled trial of ZMapp for Ebola virus infection, N Engl J Med, vol.375, p.27732819, 2016.

J. Dunning, F. Sahr, A. Rojek, F. Gannon, G. Carson et al., Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial, PLoS Med, vol.13, p.27093560, 2016.

J. Van-griensven, T. Edwards, X. De-lamballerie, M. G. Semple, P. Gallian et al., Evaluation of convalescent plasma for Ebola virus disease in Guinea, N Engl J Med, vol.374, pp.33-42, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01252702

, World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. Geneva: World Health Organization, 2015.

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, vol.105, p.24583123, 2014.

S. J. Smither, L. S. Eastaugh, J. A. Steward, M. Nelson, R. P. Lenk et al., Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Res, vol.104, p.24462697, 2014.

V. Madelain, T. Nguyen, A. Olivo, X. De-lamballerie, J. Guedj et al., Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials, Clin Pharmacokinet, vol.55, p.26798032, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-01344917

G. Piorkowski, F. Jacquot, G. Quérat, C. Carbonnelle, D. Pannetier et al., Implementation of a non-human primate model of Ebola disease: infection of Mauritian cynomolgus macaques and analysis of virus populations, Antiviral Res, vol.140, p.28132865, 2017.

T. Nguyen, J. Guedj, X. Anglaret, C. Laouénan, V. Madelain et al., Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis, vol.11, p.28231247, 2017.

V. Madelain, J. Guedj, F. Mentré, T. Nguyen, F. Jacquot et al., Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses. Antimicrob Agents Chemother, vol.61, p.27736754, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-01524308

F. Mentré, A. Taburet, J. Guedj, X. Anglaret, S. Keïta et al., Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis, vol.15, p.25435054, 2015.

X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando et al., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.514, p.25171469, 2014.

T. R. Gibb, D. A. Norwood, N. Woollen, and E. A. Henchal, Development and evaluation of a fluorogenic 5 0 nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan, J Clin Microbiol, vol.39, p.11682540, 2001.

B. B. Gowen, E. J. Sefing, J. B. Westover, D. F. Smee, J. Hagloch et al., Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Res, vol.121, p.26186980, 2015.

T. Baranovich, S. Wong, A. J. Marjuki, H. Webby, R. J. Webster et al., T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J Virol, vol.87, p.23325689, 2013.

A. I. De-Á-vila, I. Gallego, M. E. Soria, J. Gregori, J. Quer et al., Lethal mutagenesis of hepatitis C virus induced by favipiravir, PLoS ONE, vol.11, p.27755573, 2016.

A. I. De-avila, E. Moreno, C. Perales, and E. Domingo, Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus, Virus Res, vol.233, p.28322918, 2017.

E. Escribano-romero, N. J. De-oya, E. Domingo, and J. C. Saiz, Extinction of West Nile virus by favipiravir through lethal mutagenesis, Antimicrob Agents Chemother, vol.61, pp.1400-1417, 2017.

H. Sangawa, T. Komeno, H. Nishikawa, A. Yoshida, K. Takahashi et al., Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase, Antimicrob Agents Chemother, vol.57, p.23917318, 2013.

L. V. Gubareva, L. Kaiser, and F. G. Hayden, Influenza virus neuraminidase inhibitors, Lancet, vol.355, p.10711940, 2000.

T. K. Warren, R. Jordan, M. K. Lo, A. S. Ray, R. L. Mackman et al., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature, vol.531, pp.381-386, 2016.

T. W. Geisbert, L. E. Hensley, T. Larsen, H. A. Young, D. S. Reed et al., Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection, Am J Pathol, vol.163, p.14633608, 2003.

T. W. Geisbert, J. E. Strong, and H. Feldmann, Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection, J Infect Dis, vol.212, pp.91-98, 2015.

Y. Furuta, K. Takahashi, M. Kuno-maekawa, H. Sangawa, S. Uehara et al., Mechanism of action of T-705 against influenza virus, Antimicrob Agents Chemother, vol.49, p.15728892, 2005.

D. F. Smee, B. L. Hurst, H. Egawa, K. Takahashi, T. Kadota et al., Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells, J Antimicrob Chemother, vol.64, p.19643775, 2009.

C. Bai, J. Mu, D. Kargbo, Y. Song, W. Niu et al., Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705), Clin Infect Dis, vol.63, p.27553371, 2014.

O. Faye, A. Andronico, O. Faye, H. Salje, P. Boëlle et al., Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study, PLoS Med, vol.12, p.26625118, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01274833

E. P. Thi, C. E. Mire, A. C. Lee, J. B. Geisbert, J. Z. Zhou et al., Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature, vol.521, p.25901685, 2015.

D. Sissoko, S. Duraffour, R. Kerber, J. S. Kolie, A. H. Beavogui et al., Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study, Lancet Glob Health, vol.5, p.27955791, 2017.

F. Subtil, C. Delaunay, A. Keita, M. Sow, A. Touré et al., Dynamics of Ebola RNA persistence in semen: report from the Postebogui cohort in Guinea, Clin Infect Dis, vol.64, p.28329169, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01773727

M. Jacobs, A. Rodger, D. J. Bell, S. Bhagani, I. Cropley et al., Late Ebola virus relapse causing meningoencephalitis: a case report, Lancet, vol.388, issue.16, p.27209148, 2016.

A. M. Henao-restrepo, I. M. Longini, M. Egger, N. E. Dean, W. J. Edmunds et al., Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, Lancet, vol.386, issue.15, p.26248676, 2015.

S. B. Kennedy, F. Bolay, M. Kieh, G. Grandits, M. Badio et al., Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in liberia, N Engl J Med, vol.377, p.29020589, 2017.

R. L. Winslow, I. D. Milligan, M. Voysey, K. Luhn, G. Shukarev et al., Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year, JAMA, vol.317, p.28291882, 2017.

L. Oestereich, T. Rieger, M. Neumann, C. Bernreuther, M. Lehmann et al., Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever, PLoS Negl Trop Dis, vol.8, p.24786461, 2014.

L. Oestereich, T. Rieger, A. Lüdtke, P. Ruibal, S. Wurr et al., Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model for Lassa fever, J Infect Dis, vol.213, pp.934-942, 2016.

K. Best, J. Guedj, V. Madelain, X. Lamballerie, . De et al., Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies, Proc Natl Acad Sci U S A, vol.114, p.28765371, 2017.